行情

AVEO

AVEO

AVEO制药
NASDAQ

实时行情|Nasdaq Last Sale

5.32
+0.07
+1.33%
盘后: 5.35 +0.03 +0.56% 17:15 02/21 EST
开盘
5.22
昨收
5.25
最高
5.35
最低
5.03
成交量
27.56万
成交额
--
52周最高
18.50
52周最低
4.653
市值
8,555.60万
市盈率(TTM)
2.031
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AVEO价格均价为19.17,最高价位20.00,最低价为17.50。

EPS

AVEO 新闻

更多
  • Aveo Oncology to reverse split stock today; shares down 10%
  • seekingalpha · 3天前
  • AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split
  • Business Wire · 4天前
  • AVEO: Still A Speculative Buy Ahead Of FOTIVDA NDA Submission
  • Seeking Alpha - Article · 02/13 17:58
  • The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
  • Benzinga · 02/13 13:05

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

AVEO 简况

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
展开

微牛提供AVEO Pharmaceuticals, Inc.(NASDAQ-AVEO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AVEO股票新闻,以帮助您做出投资决策。